Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus DOXYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus DOXYCHEL.
ACHROMYCIN vs DOXYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic